Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Bladder Cancer and
1 other channel

Journal Scan / Research · March 20, 2023

Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Therapy vs BCG Therapy in Patients With High-Risk Non–Muscle-Invasive Bladder Cancer

JAMA Network Open

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Max Kates MD

JAMA Network Open
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
JAMA Netw Open 2023 Feb 28;6(2)e230849, IM McElree, RL Steinberg, SL Mott, MA O'Donnell, VT Packiam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated